Certified by Founder Lodge
Shinobi Therapeutics
United States - South San Francisco, CA
START UP
1 Disclosed Funding Rounds $51,000,000
0 Participating Investments
-
Founded date
2023
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Shinobi Therapeutics is developing a new class of hypoimmune CD8ab iPS-T cells for cancer and beyond by using immune evasion to unlock the full potential of iPSCs.
| Date | Round | Raised | Participating Investors |
|---|---|---|---|
| December, 13 ,2023 | Series A | $51,000,000 |
Eight Roads
F-Prime Capital
EQT Life Sciences
Fast Track Initiative
Carmot Therapeutics, Inc.
Ozette Technologies
NAPIGEN, INC.
TrueBinding
Loopworm
OTPLESS | $3,500,000 | (May 17, 2024)
Watershed Health | $13,600,000 | (May 17, 2024)
Aeropay | $20,000,000 | (May 17, 2024)
c/side | $1,700,000 | (May 17, 2024)
SINE Digital | $2,500,000 | (May 17, 2024)
